ImmunityBio, Inc. Announces 2024 Annual Meeting of Stockholders
Ticker: IBRX · Form: DEF 14A · Filed: Apr 29, 2024 · CIK: 1326110
| Field | Detail |
|---|---|
| Company | Immunitybio, Inc. (IBRX) |
| Form Type | DEF 14A |
| Filed Date | Apr 29, 2024 |
| Risk Level | low |
| Pages | 16 |
| Reading Time | 19 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: Proxy Statement, Annual Meeting, Stockholders, Virtual Meeting, ImmunityBio
TL;DR
<b>ImmunityBio, Inc. is holding its 2024 virtual annual meeting of stockholders on June 11, 2024, requiring online registration with a control number.</b>
AI Summary
ImmunityBio, Inc. (IBRX) filed a Proxy Statement (DEF 14A) with the SEC on April 29, 2024. The 2024 annual meeting of stockholders for ImmunityBio, Inc. will be held virtually on June 11, 2024, at 9:30 a.m. Pacific Time. Stockholders can attend and vote online via webcast at virtualshareholdermeeting.com/IBRX2024. A 16-digit control number, found in the Notice of Internet Availability of Proxy Materials, proxy card, or instructions, is required for participation. The filing is a Definitive Proxy Statement (DEF 14A) filed on April 29, 2024. The company was formerly known as NantKwest, Inc. (name change July 13, 2015), Conkwest, Inc. (name change April 16, 2014), and ZelleRx Corp (name change May 4, 2005).
Why It Matters
For investors and stakeholders tracking ImmunityBio, Inc., this filing contains several important signals. This filing provides essential details for stockholders to participate in the annual meeting, including how to attend virtually and vote. The proxy statement outlines the company's governance and provides information relevant to stockholder decisions at the meeting.
Risk Assessment
Risk Level: low — ImmunityBio, Inc. shows low risk based on this filing. The filing is a routine proxy statement for an annual meeting, with no immediate financial or operational disclosures that would indicate high risk.
Analyst Insight
Stockholders should review the proxy materials to understand the agenda for the annual meeting and to cast their votes on relevant proposals.
Key Numbers
- June 11, 2024 — Annual Meeting Date (2024 annual meeting of stockholders)
- 9:30 a.m. Pacific Time — Annual Meeting Time (2024 annual meeting of stockholders)
- 16-digit — Control Number Length (Required for meeting participation)
- 20240429 — Filing Date (DEF 14A filing date)
Key Players & Entities
- ImmunityBio, Inc. (company) — Registrant
- June 11, 2024 (date) — Date of Annual Meeting
- virtualshareholdermeeting.com/IBRX2024 (url) — Webcast link for meeting
- NantKwest, Inc. (company) — Former company name
- Conkwest, Inc. (company) — Former company name
- ZelleRx Corp (company) — Former company name
- 2024 (date) — Year of Annual Meeting
- DEF 14A (filing_type) — Filing type
FAQ
When did ImmunityBio, Inc. file this DEF 14A?
ImmunityBio, Inc. filed this Proxy Statement (DEF 14A) with the SEC on April 29, 2024.
What is a DEF 14A filing?
A DEF 14A is a definitive proxy statement sent to shareholders before annual meetings, covering executive compensation, board nominations, and shareholder votes. This particular DEF 14A was filed by ImmunityBio, Inc. (IBRX).
Where can I read the original DEF 14A filing from ImmunityBio, Inc.?
You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by ImmunityBio, Inc..
What are the key takeaways from ImmunityBio, Inc.'s DEF 14A?
ImmunityBio, Inc. filed this DEF 14A on April 29, 2024. Key takeaways: The 2024 annual meeting of stockholders for ImmunityBio, Inc. will be held virtually on June 11, 2024, at 9:30 a.m. Pacific Time.. Stockholders can attend and vote online via webcast at virtualshareholdermeeting.com/IBRX2024.. A 16-digit control number, found in the Notice of Internet Availability of Proxy Materials, proxy card, or instructions, is required for participation..
Is ImmunityBio, Inc. a risky investment based on this filing?
Based on this DEF 14A, ImmunityBio, Inc. presents a relatively low-risk profile. The filing is a routine proxy statement for an annual meeting, with no immediate financial or operational disclosures that would indicate high risk.
What should investors do after reading ImmunityBio, Inc.'s DEF 14A?
Stockholders should review the proxy materials to understand the agenda for the annual meeting and to cast their votes on relevant proposals. The overall sentiment from this filing is neutral.
How does ImmunityBio, Inc. compare to its industry peers?
ImmunityBio, Inc. operates in the biotechnology sector, focusing on developing therapies.
Are there regulatory concerns for ImmunityBio, Inc.?
The filing is made under the Securities Exchange Act of 1934, specifically Section 14(a) concerning proxy solicitations.
Industry Context
ImmunityBio, Inc. operates in the biotechnology sector, focusing on developing therapies.
Regulatory Implications
The filing is made under the Securities Exchange Act of 1934, specifically Section 14(a) concerning proxy solicitations.
What Investors Should Do
- Review the proxy statement for details on proposals to be voted on at the annual meeting.
- Ensure you have your 16-digit control number ready for virtual meeting access.
- Vote your shares prior to or during the virtual meeting.
Key Dates
- 2024-06-11: Annual Meeting of Stockholders — Key date for stockholder participation and voting.
- 2024-04-29: Filing of Definitive Proxy Statement — Indicates the availability of proxy materials for the upcoming annual meeting.
Year-Over-Year Comparison
This is a DEF 14A filing for the 2024 annual meeting, following previous filings related to company operations and governance.
Filing Stats: 4,833 words · 19 min read · ~16 pages · Grade level 13.1 · Accepted 2024-04-29 16:18:07
Filing Documents
- ibrx-20240429.htm (DEF 14A) — 1275KB
- ibrx-20240429_g1.jpg (GRAPHIC) — 1KB
- ibrx-20240429_g2.jpg (GRAPHIC) — 32KB
- ibrx-20240429_g3.jpg (GRAPHIC) — 226KB
- ibrx-20240429_g4.jpg (GRAPHIC) — 29KB
- ibrx-20240429_g5.jpg (GRAPHIC) — 4KB
- ibrx-20240429_g6.jpg (GRAPHIC) — 110KB
- ibrx-20240429_g7.jpg (GRAPHIC) — 108KB
- ibrx-20240429_g8.jpg (GRAPHIC) — 130KB
- ibrx-20240429_g9.jpg (GRAPHIC) — 116KB
- 0001326110-24-000054.txt ( ) — 3575KB
- ibrx-20240429.xsd (EX-101.SCH) — 3KB
- ibrx-20240429_def.xml (EX-101.DEF) — 4KB
- ibrx-20240429_lab.xml (EX-101.LAB) — 6KB
- ibrx-20240429_pre.xml (EX-101.PRE) — 4KB
- ibrx-20240429_htm.xml (XML) — 69KB
EXECUTIVE COMPENSATION
EXECUTIVE COMPENSATION 27 Our Current Named Executive Officers 27 Processes and Procedures for Executive Compensation 27 Employment Arrangements with Our Current Named Executive Officers 28 Merger or Change in Control 30 Other Compensation Policies 31 Tax and Accounting Considerations 31
Executive Compensation Clawback Policy
Executive Compensation Clawback Policy 31
EXECUTIVE COMPENSATION TABLES
EXECUTIVE COMPENSATION TABLES 32 Summary Compensation Table 32 All Other Compensation – Other Compensation and Perquisites 33 Grants of Plan-Based Awards 33 Outstanding Equity Awards at Fiscal Year-End 34 Option Exercises and Stock Vested 35 EQUITY COMPENSATION PLAN INFORMATION 35 DIRECTOR COMPENSATION 36 2023 Director Compensation Policy 36 Other Compensation Details 36 Equity Awards 37 | i | Non-Employee Director Stock Ownership Policy 37 Director Compensation Table 38 PAY VERSUS PERFORMANCE 39 Pay Versus Performance Table 39 Narrative Disclosure to Pay Versus Performance Table 41
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 42 PROPOSAL 4 – RATIFICATION OF SELECTION OF INDEPENDENT REGISTERED PUBLIC ACCOUNTANTS 45 Board Recommendation 45 AUDIT MATTERS 46 Audit Committee Report 46 Fees Paid to Independent Registered Public Accounting Firm 47 ANNUAL REPORT ON FORM 10-K 47 CERTAIN RELATIONSHIPS AND RELATED-PARTY TRANSACTIONS 48 Cambridge Investment 48 Related-Party Debt 49 Other Related-Party Agreements and Arrangements 57 Indemnification Agreements 61 Policies for Approval of Related-Party Transactions 61 OTHER MATTERS 62 Stockholder Proposals for the 2025 Annual Meeting 62 Availability of Bylaws 63 Code of Global Business Conduct and Ethics 63 Householding of Proxy Materials 63 No Incorporation by Reference 63 APPENDIX A: IMMUNITYBIO, INC. 2015 EQUITY INCENTIVE PLAN A- 1 | ii | Table of Contents PROXY STATEMENT As a smaller reporting company for the fiscal year ended December 31, 2023, ImmunityBio is electing to comply with the scaled disclosure requirements applicable to smaller reporting companies pursuant to SEC rules for many of the items that are incorporated by reference into Part III of its Annual Report on Form 10-K. These scaled disclosure requirements include reduced disclosure about the company's executive compensation arrangements. Please note that certain of the executive compensation disclosure required to be described for a smaller reporting company is presented in tabular form for ease. The information provided in the "Questions and Answers" format below is for your convenience only and is merely a summary of the information contained in this proxy statement. You should read the entire proxy statement carefully. Questions and Answers about the Proxy Materials and Annual Meeting Why am I receiving these materials? This proxy statement and the enclosed form of proxy are posted in connection with the solicitation of proxies by the Board for use